Evidence map›Paper›PMID 41497446›Full record

ArticleNeuro-oncology advances

Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation.

Talia Eligator, Jit Chatterjee, Shintaro Yamada, Anthony Kirchner, Hareesh B Nair, Jason R Fangusaro, David H Gutmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Talia EligatorDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.).
Jit ChatterjeeDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.).ORCID https://orcid.org/0000-0002-2444-9748
Shintaro YamadaDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.).
Anthony KirchnerDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.).
Hareesh B NairDepartment of Molecular and Translational Medicine, Texas Tech University Health Science Center,  Rick Francis St, El Paso, Texas, 79905 (H.B.N.).
Jason R FangusaroDepartment of Pediatrics, Children's Healthcare of Atlanta and the Aflac Cancer Center, Emory University School of Medicine, Atlanta, Georgia.
David H GutmannDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO (T.E., J.C., S.Y., A.K., D.H.G.).ORCID https://orcid.org/0000-0002-3127-5045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Authenticated preclinical brain tumor models provide unprecedented opportunities to evaluate next-generation treatments. However, some therapies with robust anti-tumor activity in mice fail in human trials, highlighting the need to better prioritize candidates for clinical translation. Herein, we implemented a head-to-head preclinical strategy using a well-characterized murine model of NF1-optic pathway glioma ( Methods: Results: While all agents restored normal tissue architecture, reduced ON proliferation, and decreased TME soluble mediator and tumor cell marker RNA expression, only lamotrigine and mirdametinib also reduced ON volume. Everolimus, lamotrigine, and HBS-101 restored RNFL thickness to wild-type levels, whereas carboplatin showed a trend towards normalization. Conclusions: This referential preclinical study design affords direct head-to-head comparisons of investigational therapies relative to SOC treatment using clinically meaningful outcomes (OPG growth and RNFL thickness). Using this strategy, lamotrigine emerged as the most promising therapy for limiting tumor progression and vision loss in

Indexed as

carboplatinlamotriginelow-grade gliomaneurofibromatosisoptic gliomapediatric brain tumorvision

Identifiers

PMID41497446
PMCPMC12768503

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.